Eisai Innovation, Inc.

Eisai Innovation, Inc. is the corporate venture capital subsidiary of Eisai Co., Ltd., established in August 2019. The firm aims to identify and invest in innovative healthcare companies that align with Eisai's mission to contribute to patients and their families. Their investment focus includes cutting-edge drug discovery platforms, new modalities, and leading biotechnology in areas such as neurology, oncology, and global health. Additionally, they support investments in drug discovery technologies in other areas where significant future innovations are anticipated. The firm's investment strategy encompasses a wide range of stages, from seed to pre-IPO, and spans various geographical regions, including the United States, Japan, China, and several European and emerging markets. They have a diverse portfolio across multiple industries, including healthcare, biotechnology, pharmaceuticals, digital health, and medical devices. Investment sizes typically range from $5 million to $50 million. Eisai Innovation, Inc. has been recognized for its contributions to the pharmaceutical startup ecosystem, notably being selected as a registered venture capital firm by the Japan Agency for Medical Research and Development (AMED) in November 2024. This recognition underscores their commitment to accelerating drug discovery innovation and establishing an ecosystem platform to address diseases with high unmet medical needs.

Innovative healthcare solutions, Alignment with Eisai's mission, Potential for significant impact in target therapeutic areas, Scalable business models, Strong management teams, Technological differentiation, Regulatory compliance, Market readiness, Sustainable development goals alignment, Clear exit strategies